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Summary The expression of the major histocompatibility complex (MHC) class I and II antigens and lymphocyte function-associated antigen-3 (LFA-3) was investigated using immunohistochemical staining of bladder tissue sections from 18 patients with transitional cell carcinoma (TCC) and two normal bladder specimens. The There has been considerable debate as to whether immunosurveillance is of relevance in providing protection against development of malignancy (for review see Oliver, 1985) . The recent evidence that use of T cell growth factor, interleukin-2 can produce long term remission in patients with renal cell carcinoma and malignant melanoma , has led to a rebirth of interest in this debate, particularly with the demonstration that alterations in tumour major histocompatibility complex (MHC) expression may be important in determining which patients respond to treatment (Cohen et al., 1987) .
The recognition of neo-antigens by T cells occurs in the context of MHC molecules which are polymorphic cell surface glycoproteins expressed in two forms: class I (HLA-A,B,C) and class II (HLA-D). These molecules act as restriction elements for presentation of foreign antigens to mostly CD8 positive T cytotoxic (CTL) and CD4 positive T helper cells respectively (Zinkernagal & Doherty, 1979) . Individual HLA allele products, even those mapping to the same locus, vary in their ability to present different antigen epitopes (Gotch et al., 1987; McMichael et al., 1986) .
Class I antigens are composed of a heavy chain and a light chain, P2 microglobulin, whose association with the heavy chain is required for surface expression of class I antigens (Arce Gomez et al., 1978 ). An additional factor contributing to efficiency of CTL activity is the interaction between CD2 molecules on T cells and lymphocyte function-associated antigen-3 (LFA-3) on target cells in a non-antigen-specific manner (Krensky et al., 1984) . Evidence that loss of MHC class I antigen on tumours led to increased malignancy first came from studies of murine tumours (for review see Festenstein & Schmidt, 1981) . Later studies showed that transfection of the missing MHC class I gene into these tumour cells led to a reversal of tumourgenicity or of metastatic potential (Hui et al., 1985; Wallich et al., 1985) and more importantly, after immunisation with such altered tumour, exposed mice were resistant to the original class I deficient tumour (Hui et al., 1985) .
Increasingly it is being recognised that loss of class I antigen expression may be a frequent event in a human malignancy. Class I antigen loss has been demonstrated in a substantial proportion of colon adenocarcinomas (Smith et al., 1988; Rees et al., 1988; Momburg et al., 1986) , breast carcinoma (Fleming et al., 1981) and Burkitt lymphomas (Masucci et al., 1987) (Brodsky et al., 1979) ; HC-10 detects HLA-A,B,C free heavy chain (i.e. not associated with P2m) with a preference for HLA-B products (Stam et al., 1986) ; PA 2.6 and W6/32 detect all P2m-associated HLA-A,B,C antigens (Brodsky et al., 1979) ; GAP A3 detects HLA-A3 (Berger et al., 1982) 4s  4s  2  N  4s  4s  4s  --4s  4s   3  N  4s  4s  4s  4s  4s  4m  -4s  4s  4  I  4s  4m  4s   ---4m   4m  5  I   4s  4m  4s  4m  4w  -3m  4s  6  N  4s  4m  4s  4s  4w  4m  4w  4m   4s   7  I  4s  0  4s  4m L243 detects HLA-DR (Lampson & Levy, 1980) ; B7/21 detects HLA-DP (Watson et al., 1983) and anti-CD3, -CD4 and -CD8 Mabs (Ortho Pharmaceutical) detect total T, T helper and T cytotoxic lymphocytes subsets respectively.
The immunohistochemical specificity of the Mabs directed against HLA-A,B,C allele products was demonstrated by their reactivity on tumour stroma in a series of 12 breast carcinomas, which has been HLA-typed (Dr J.G. Bodmer, unpublished data).
Immunohistochemistry
Frozen sections were cut using a cryostat at a thickness of 7 1m, placed on microscope slides and kept at -80°C until used. The sections were stained as described by Smith et al. (1989) . The area of tumour sections varied from 9 to 35 mm2. Selected cases with adequate material had repeat testing to establish acceptable reproducibility.
Assessment
Immunohistochemical staining on epithelium and stroma was assessed in normal bladder (where available) and neoplastic bladder tissues. HLA-A,B,C type was deduced from the reaction of the Mabs directed against polymorphic HLA-A,B,C determinants with tumour stroma. Expression of antigens on tumour cells were graded semi-quantitatively by comparison to the degree of expression on the stromal cells (see Table I ).
Results

HLA-A,B,C antigens
Staining of tissue sections from two normal bladders showed strong positive staining in 100% of epithelial cells with Mab against class I antigens (W6/32 and PA2.6) and LFA-3 (TS2/ 9) and no staining for class II antigens defined by monoclonal antibody L243.
The tumour cells of one of 18 cases showed a complete loss of all HLA-A,B,C molecules (Table I , case 18, Figure 1 Although the expression of HLA-A,B,C free heavy chain (unassociated with P2-microglobulin) as detected by Mab HC-10 usually mirrored the expression of mature (p2-microblobulin associated) heavy chain as detected by Mab PA2.6, in cases 7, 10 and 13 free heavy chain was undetectable despite moderate to strong expression of mature heavy chain (Table I) this lower definition of loss, only four of 18 could be said to have totally normal expression of HLA-A,B,C with the available Mabs against monomorphic and polymorphic determinants.
The pattern of antigen expression on tumour cells using Mabs specific for class II antigens was heterogeneous and often focal. Although nine of nine were positive for the 'core' HLA-D antigen recognised by Mab TU39. Seven of nine were positive for DR, five of nine positive for DQ and three of nine positive for DP. HLA-DP and DQ expression mirrorea HLA-DR and in no case was a tumour observed to be HLA-DR negative yet HLA-DP or DQ positive. There was not any direct correlation between the expression of HLA-D h antigens and that of degree of T cell infiltration (see below)
into the tumour area. In one case (11) strong expression of HLA-DR antigen was observed on normal epithelium adjacent to HLA-DR negative neoplastic epithelium (Figure 3) .
LFA-3 was expressed with moderate to strong intensity in 16 of 18 cases. There were two cases of complete LFA-3 loss (cases 15, 18, Table I , Figure 4 ) and in both cases the HLA-A,B,C antigens were either lost or down-regulated.
In a subset of the cases, the nature of tumour infiltrating lymphocytes was investigated using Mabs specific for A different T cell subtypes. T cells (CD4 >>CD8) positive were found to be present in tumour stroma (11 of 12 cases) the intra-epithelially (eight of 12).
Discussion
Although post-mortem material is not ideal for such studies because of risk of autolysis and problems of induction of class II antigen by terminal bladder infection, the results do confirm the observations from larger studies (Gardiner et al., 1985) that class I but not class II is expressed on normal usothelium.
Against this background the results of these tumour studies have demonstrated that HLA-A,B,C antigen exprest sion is demonstrated in over a third of TCCs. Also, there was a definite case (13) of selective loss of HLA-Bw6 antigen in the presence of normal expression of other HLA-A,B,C products, two cases of complete loss of LFA-3 molecules (both of which also had either complete or partial loss of all class I antigens) and, finally, a single example where HLA-D antigen expression was observed on normal epithelium adjacent to negative neoplastic epithelium. All of these abnormalities in the expression of a immunoregulatory molecules could be capable of conferring a selective growth advantage to tumour cells by enabling escape from T cell immune attack directed against tumour specific antigens.
The selective loss of HLA-A,B,C allele products from neoplastic cells has previously been reported in other tumour types. These include Burkitt lymphoma (Masucci et al., 1987) and colorectal adenocarcinoma (Smith et al., 1989; Rees et al., 1988; Momburg et al., 1989) . Such a selective loss of class I antigens could confer resistance to immune attacks against tumour, given the varying ability of different HLA-A,B,C allele products to present antigen epitopes to cytotoxic T cells. Thus, the loss of a single allele product could be functionally equivalent, in terms of escape from T cell attack, to the loss of all HLA-A,B,C molecules. Selective losses of HLA-A,B,C allele products could result from a single genetic mutation, whereas loss of all HLA-A,B,C antigens (e.g. case P 18) would usually require more than a single mutation. The incidence of colorectal adenocarcinomas with abnormal HLA-A,B,C antigen expression (11 of 30 cases) (Smith et al., 1989) was similar to that reported in this study of bladder g tumours. However, in contrast to the situation demonstratable in the bladder, most HLA-A,B,C loss in colorectal carcinomas was of individual HLA-A,B,C allele products and not a generalised loss of all HLA-A,B,C antigens as in bladder where there was an unexpectedly high frequency of loss of free heavy chain. This deserves further investigation. The absence of detectable HLA-A,B,C free heavy chain in tumours expressing mature HLA-A,B,C antigen was seen in three cases (7, 10 and 13). The basis of this interesting observation may be a slow rate of HLA-A,B,C antigen synthesis by tumour cells.
Class II antigen expression as detected by TU39 Mab was often focal and of variable intensity on tumour cells of all nine case studies. Locus product specific Mabs for DR, DP and DQ also showed patch areas of positivity on the tumour cells. Similar results regarding the expression of class II antigens on neoplastic bladder epithelium were also reported by Gardiner et al. (1985) .
The significance of class II antigen expression on bladder tumour cells is not clear, but it is conceivable that the detection of tumour antigen by infiltrating T cells results in the production of cytokines which in turn stimulate induction of tumour class II products. The presence of T cells in both tumour stroma and intra-epithelial areas is agreement with this hypothesis. Supportive evidence comes also from the observation that it has been possible to use interleukin-2 (IL-2) to expand activated T cells from six of 18 of these tumour biopsies using 11-2 after culture of tumour cell suspension (A. Nouri, in preparation).
The complete loss of LFA-3 molecules from tumour cells occurred in two of 18 cases. This may give tumour additional advantage to escape from immune surveillance given the importance of LFA-3 binding to CD2 molecules on CD8 cytotoxic cells to initate cytoxicity. The fact that LFA-3 loss is not, however, confined to bladder neoplasia, having been also demonstrated in colorectal adenocarcinoma (Smith et al., 1989) and Burkitt lymphoma (Gregory et al., 198P.) would also support this observation. It is interesting to note that the two cases (15 and 18) showing LFA-3 losses also showed complete or major down-regulation of HLA-A,B,C antigens.
Given the focal nature of these antigen losses and the small size of tumour sample tested, it is obvious that the frequency of loss reported in this study is a minimum incidence.
Attempts were made to correlate the presence or absence of invasion (according to UICC system) with class I antigen expression on tumour cells. No significant association was demonstrated in the small numbers tested but it is of interest that the tumour not expressing any HLA-A,B,C antigen or LFA-3 (case 18), a further tumour not expressing LFA-3 (case 14) and the tumour showing the loss of HLA-Bw6 (case 13) were all invasive and no non-invasive tumour showed this degree of loss. More extensive testing is required to clarify whether loss of these immuno-regulatory molecules does lead to selective growth advantage to tumour.
